- Clinical study of rubidazone (22 050 R.P.), a new daunorubicin-derived compound, in 170 patients with acute leukemias and other malignancies. Jacquillat, C., Weil, M., Gemon-Auclerc, M.F., Izrael, V., Bussel, A., Boiron, M., Bernard, J. Cancer (1976)